General Updates

Neuland Laboratories Limited I( neuland 11th floor (5th level), Phoenix IVY Building, Plot No.573A-I11, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India. CONTACT 040 67611600 / 67611700 neuland@neulandlabs.com neulandlabs.com November 3, 2026 BSE Limited The National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Exchange Plaza, Street, Mumbai-400 001 Sandra Kurla Complex Sandra (E), Mumbai - 400 001 Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ Dear Sir/Madam, Sub: Outcome of Board Meeting Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors at their meeting held on even date, i.e. November 3, 2026, have considered and approved the following: A. Financial Results Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended September 30, 2026. A copy of the Unaudited Financial Results for the quarter and half year ended September 30, 2026, together with the limited review rep9rts (Standalone & Consolidated) by the Statutory Auditors of the Company are enclosed herewith. B. Capital expenditure of ~ 47 .1 crores towards the acquisition of a land parcel admeasuring Ac.6-00 Gts situated at Domadugu Village, Sangareddy District, Telangana., including other related expenditure. The requisite details are as under: a. Existing Capacity NIA b. Existing Capacity Utilization NIA c. Proposed Capacity Addition N/A d. Period within which the proposed capacity is to be added N/A e. Investment required ~ 47.1 crores (incl GST) f. Mode of financing Through internal accruals g. Rationale For future capacity expansion The meeting of Board of Directors of the Company commenced at 9:30 a.m. and concluded at 3.34 p.m. The above information will also be available on the website of the Company at www.neulandlabs ..c om. This is for your information and records. Thanking you, Yours Sincerely, For Neuland Labo Sarada Bhamidip Company Secreta Encl: As above REGISTERED OFFICE: 11th floor (5th level), Phoenix IVY Building, Plot No.573A-III, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India. CIN No. L85195TG1984PLC00 4393 MS KA & Associates LLP 1101 /B, Manjeera Trinity Corporate JNTU-Hitech City Road, Kukatpally (Formerly known as MS KA ft Associates) Telangana, Hyderabad 500072, INDIA Chartered Accountants Independent Auditor's Review Report on consolidated unaudited financial results of Neuland Laboratories Limited for the quarter and year to date pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Neuland Laboratories Limited 1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Neuland Laboratories Limited ("the Holding Company"), its subsidiaries, (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended September 30, 2026 and the year to-date results for the period from April 01, 2026 to September 30, 2026 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations"). 2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS 34") and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable. 4. This Statement includes the results of the Holding Company and the following entities: Sr. No Name of the Entit Re lat an 1 Neu land Laboratories K. K., Ja an Wholl 2 Neuland Laboratories Inc. USA Wholl wned Subsid 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +91 22 6974 0200 I LLPIN: ACT-3789 Ahmed<1bad I Bengaluru I Chandigarh I Chennai I Coimbatore I Goa I Gurugram I Kochi I Kolkata I Mumbai I Pune www mska,in MSKA & Associates LLP (Formerly known as M 5 KA 8: Associates) Chartered Accountants 6. The Statement includes the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflects total assets of Rs.1,264. 32 as at September 30, 2026 and total revenue of Rs. 1,024.99 lakhs and Rs.1,631.53 lakhs, total net profit after tax of Rs. 49. 75 lakhs and Rs.80.87 lakhs and total comprehensive income of Rs. 35.26 lakhs and Rs.57.48 lakhs for the quarter ended September 30, 2026, and for the period from April 01, 2026, to September 30, 2026, respectively, and cash flows (net) of Rs. 162.79 Lakhs for the period from April 01, 2026, to September 30, 2026, as considered in the Statement. This interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group. Our conclusion is not modified in respect of the above matter with respect to our reliance on the interim financial information certified by the management. For M S K A & Associates LLP (Formerly known as MS KA & Associates) Chartered Accountants IC~A irm Registration No.105047W/W101187 Pra ashChandra Bhutada Partner Membership No.: 404621 uo1N: 2~ l/o Yb~. I Mt en-/ R~ ~9b Place: Hyderabad Date: November 03, 2026 Registered Office: 602, Raheja nt,mium, Western Express Highway, Goregaon (East), Mumbai·400063, Maharashtra, India Tel: +91 22 6974 0200 I LLPIN: ACT•3789 Ahmec!abad I Bengaluru I Chandigarh I Chennai I Coimbatore I Goa I Gurugram I Hyderabad I Koehl I Kolkata I Mumbai I Pune www mska in Nculand Laboratories Limited /{ [Showing first 8,000 characters — download PDF for full document]